Chris Cournoyer

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

Emerson Hospital has proudly served our community for more than a century. With hundreds of doctors serving over 300,000 patients across the region, we have grown to be more than a hospital you go to when you are sick. We are here to keep you well. At Emerson, our strong connection to our community and patients enables us to deliver the best possible care. We know Emerson is special. That is why we rebranded to tell our story. We are Emerson Health, and we are proud to serve our community with excellence, personalized. EMERSON HEALTH — EXCELLENCE PERSONALIZED It is easy to feel lost in the world of healthcare. When you need help, you want professionals who bring their best and understand you. The expertise you are looking for is available right here, close to home. At Emerson Health:​ We understand that healthcare is personal. ​ We put patients first. ​ We take time to listen. ​ We see our patients as people, not their condition. ​ We are here for patients through every stage of life. Our new logo reflects the care continuum, starting at the center and taking us through life’s journey. ​Our green colors represent our commitment​ to personalized care, and our blue colors reflect the excellence that we deliver.

Headquartered in Marlborough, Massachusetts, BJ's Wholesale Club is a leading operator of membership warehouse clubs in the Eastern United States. The company currently operates over 239 clubs and more than 169 BJ's Gas® locations in 20 states. Explore career opportunities at BJ's and join our team today: www.bjs.com/careers

Spok is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 100 million messages each month through their Spok® solutions. When seconds count and patients’ lives are at stake, Spok enables smarter, faster clinical communication.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

Emerson Hospital has proudly served our community for more than a century. With hundreds of doctors serving over 300,000 patients across the region, we have grown to be more than a hospital you go to when you are sick. We are here to keep you well. At Emerson, our strong connection to our community and patients enables us to deliver the best possible care. We know Emerson is special. That is why we rebranded to tell our story. We are Emerson Health, and we are proud to serve our community with excellence, personalized. EMERSON HEALTH — EXCELLENCE PERSONALIZED It is easy to feel lost in the world of healthcare. When you need help, you want professionals who bring their best and understand you. The expertise you are looking for is available right here, close to home. At Emerson Health:​ We understand that healthcare is personal. ​ We put patients first. ​ We take time to listen. ​ We see our patients as people, not their condition. ​ We are here for patients through every stage of life. Our new logo reflects the care continuum, starting at the center and taking us through life’s journey. ​Our green colors represent our commitment​ to personalized care, and our blue colors reflect the excellence that we deliver.

Headquartered in Marlborough, Massachusetts, BJ's Wholesale Club is a leading operator of membership warehouse clubs in the Eastern United States. The company currently operates over 239 clubs and more than 169 BJ's Gas® locations in 20 states. Explore career opportunities at BJ's and join our team today: www.bjs.com/careers

We are The Customer Company: Harte Hanks is a global customer experience company focused on bringing companies closer to customers for 100 years. Whether it’s through deeply personalized omnichannel marketing programs designed to engage and motivate the right people at the right moments; customer care services that transform negative experiences into positive outcomes and truly make customers feel cared for; or fulfillment and logistics capabilities that efficiently put products directly in the hands of customers, we remain relentlessly dedicated to removing friction and creating enduring connections. With an average employee tenure of 10 years and an average client tenure of 12 years, we’ve always had our partners’ backs, helping them navigate the B2C and B2B marketing landscape.